Primrose Bio and ExPLoRNA Therapeutics Collaborate on mRNA Therapies

Primrose Bio has initiated a strategic partnership with ExPLoRNA Therapeutics with the goal of advancing mRNA medicine development and marketing. The collaboration leverages Primrose Bio's expertise in engineering high-performance RNA polymerases (Prima RNApols), which are crucial for enhancing mRNA synthesis yield. This technology is beneficial as it not only reduces the presence of double-stranded RNA (dsRNA) but also lowers production costs, thereby meeting the stringent manufacturing demands for various mRNA applications.

ExPLoRNA Therapeutics is renowned for its innovations in mRNA, specifically focusing on new cap analogues that are essential for effective protein production. The technology developed by ExPLoRNA enhances protein production, minimizes dsRNA formation, and reduces in vitro transcription (IVT) costs, leading to significant improvements in therapeutic effectiveness.

Primrose Bio's CEO, Helge Zieler, expressed enthusiasm about the collaboration, highlighting that combining ExPLoRNA’s advanced mRNA cap analogs with Primrose Bio’s RNA polymerases would result in broader manufacturing and design options for companies developing mRNA therapeutics and vaccines. According to Zieler, this partnership aims to facilitate access to the most efficient capping chemistry available in the market.

The collaboration between Primrose Bio and ExPLoRNA is expected to lead to the joint development of RNA polymerases and capping compounds that are co-optimized to improve mRNA quality, manufacturing efficiency, and the safety and efficacy of therapies. The partnership intends to provide enhanced manufacturing solutions and new design options through advanced capping chemistry for mRNA drug developers.

Jacek Jemielity, CEO of ExPLoRNA Therapeutics, emphasized that the partnership aims to advance mRNA as a modality from its initial applications to the next generation. He stated that the goal is to create optimal synergies between their cap analogs and novel polymerases, surpassing current manufacturing processes and elevating what is achievable with mRNA today.

In addition to this partnership, in March 2024, Primrose Bio announced a strategic collaboration with Intravacc, a contract development and manufacturing organization. This collaboration is focused on enhancing the development and supply of conjugate vaccines.

This cooperative effort between Primrose Bio and ExPLoRNA Therapeutics signifies a significant step towards improving the development and manufacturing processes of mRNA medicines, potentially leading to more effective and efficient therapeutic options in the future.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!